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Abstract 
Background: Visceral fat plays a central role in the development of metabolic syndrome and atherosclerotic car‑
diovascular diseases. The association of visceral fat accumulation with cardio‑metabolic diseases has been reported, 
but the impact of visceral fat on the gene expression profile in peripheral blood cells remains to be determined. The 
aim of this study was to determine the effects of visceral fat area (VFA) and subcutaneous fat area (SFA) on the gene 
expression profile in peripheral blood cells of obese subjects.
Methods: All 17 enrolled subjects were hospitalized to receive diet therapy for obesity (defined as body mass index, 
BMI, greater than 25 kg/m2). VFA and SFA were measured at the umbilical level by computed tomography (CT). Blood 
samples were subjected to gene expression profile analysis by using SurePrint G3 Human GE Microarray 8 × 60 k ver. 
2.0. The correlation between various clinical parameters, including VFA and SFA, and peripheral blood gene expression 
levels was analyzed.
Results: Among the 17 subjects, 12 had normal glucose tolerance or borderline diabetes, and 5 were diagnosed with 
type 2 diabetes without medications [glycated hemoglobin (HbA1c); 6.3 ± 1.3%]. The mean BMI, VFA, and SFA were 
30.0 ± 5.5 kg/m2, 177 ± 67 and 245 ± 131 cm2, respectively. Interestingly, VFA altered the expression of 1354 genes, 
including up‑regulation of 307 and down‑regulation of 1047, under the statistical environment that the parametric 
false discovery rate (FDR) was less than 0.1. However, no significant effects were noted for SFA or BMI. Gene ontology 
analysis showed higher prevalence of VFA‑associated genes than that of SFA‑associated genes, among the genes 
associated with inflammation, oxidative stress, immune response, lipid metabolism, and glucose metabolism.
Conclusions: Accumulation of visceral fat, but not subcutaneous fat, has a significant impact on the gene expression 
profile in peripheral blood cells in obese Japanese subjects.
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Background
Increasing evidence demonstrates that excess visceral 
fat locates upstream of the metabolic syndrome, a clus-
ter of diabetes, dyslipidemia, and hypertension, which is 
associated with atherosclerotic cardiovascular diseases 
[1]. In a series of clinical studies, we have shown that 
visceral fat area (VFA), but not subcutaneous fat area 
(SFA), correlates significantly and strongly with cardio-
metabolic diseases [2, 3]. Various groups, including ours, 
have focused on the underlying molecular mechanism 
and links between visceral fat accumulation and cardio-
metabolic diseases [4, 5]. Some of the discussed molec-
ular pathological links between visceral adiposity and 
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cardio-metabolic diseases include dysregulation of adipo-
cytokines [1], chronic low-grade inflammation of visceral 
fat tissue [6], and harmful changes in gut microbiota [7]. 
However, the exact mechanism(s) remains unresolved.
We have also examined the role of gene expression 
profile in peripheral blood cells, and reported that vis-
ceral adiposity can alter the expression profiles of various 
genes in peripheral blood cells, including those involved 
in circadian rhythm and inflammation [8, 9]. However, 
in these studies, visceral adiposity, including VFA and 
SFA, was not assessed by modern precision technology 
such as computed tomography (CT). In addition, impact 
of SFA on gene expressions in peripheral blood cells was 
not determined. Moreover, most of the enrolled subjects 
were overt type 2 diabetes patients (HbA1c; 8.1 ± 2.2%) 
in our previous study [8, 9], suggesting that gene expres-
sion profile in peripheral blood cells influenced by these 
parameters. Other groups also investigated the impact 
of VFA and/or SFA on the expression of various genes in 
peripheral blood cells. For example, Lee et al. [10] found 
a significant association between VFA, but not SFA, and 
sirtuin 1 (SIRT1) mRNA level in peripheral blood mono-
nuclear cells.
The aim of the present study was to define the associa-
tion of VFA and SFA determined by CT, with the gene 
expression profile in peripheral blood cells in obese sub-
jects free of overt diabetes.
Methods
Study population
The enrolled subjects were hospitalized at Sumitomo 
Hospital between February 2012 and April 2014 to 
receive calorie-restricted diet therapy for obesity. Sub-
jects with type 1 diabetes mellitus, cancer, autoimmune 
diseases, and infectious diseases were excluded from the 
present study. Patients treated with glucose-lowering 
agents were also excluded. Written informed consent was 
obtained from each patient after explaining the purpose 
of study. The study protocol was approved by the human 
ethics committees of Sumitomo Hospital and Osaka 
University. The study was also registered with the Uni-
versity Hospital Medical Information Network (UMIN 
#000001663).
Clinical parameters
Obesity was defined as body mass index (BMI) greater 
than 25 kg/m2 according to the criteria of the Japan Soci-
ety for the Study of Obesity [11]. VFA and SFA were 
measured on the cross-sectional CT slice at the umbili-
cal level [12]. Waist circumference was measured with 
a tape at the umbilical level in standing position. Serum 
adiponectin concentration was measured by a latex 
particle-enhanced turbidimetric immunoassay with a 
human adiponectin latex kit (Otsuka Pharmaceutical 
Co., Tokyo, Japan). The homeostasis model − assessment 
of insulin resistance (HOMA-IR) was calculated by the 
equation: [HOMA-IR =  fasting insulin (µU/mL) ×  fast-
ing glucose (mg/dL)/405]. Type 2 diabetes mellitus and 
borderline diabetes were defined according to the criteria 
of the Japan Diabetes Society [13]. Briefly, diabetes was 
defined as fasting glucose of ≥126 mg/dL, casual glucose 
of ≥200  mg/dL, or HbA1c of ≥6.5%. Hypertension was 
defined as systolic blood pressure (SBP) of ≥140 mm Hg, 
diastolic BP (DBP) of ≥90 mm Hg, or treatment with anti-
hypertensive agents. Dyslipidemia was defined as fasting 
triglycerides (TG) of ≥150 mg/dL, high-density lipopro-
tein cholesterol (HDL-C) of <40  mg/dL, or low-density 
lipoprotein cholesterol (LDL-C) of ≥140 mg/dL, or treat-
ment with lipid-lowering agents. LDL-C was calculated 
using the Friedewald formula, except in cases with TG 
of >400 mg/dL. The estimated glomerular filtration rate 
(eGFR) was calculated by using the following formula: 
[eGFR = 194 × (serum creatinine−1.094) × (age−0.287) × F 
(male, F  =  1; female, F  =  0.739)] [14]. Intima-media 
thickness (IMT) of common carotid artery was measured 
by echography (HI VISION Preirus; Hitachi, Tokyo).
Microarray analysis
Blood samples were collected into PaxGene Blood RNA 
tubes (PreAnalytiX, Qiagen Inc., Valencia, CA) before 
breakfast and left to stand for 2 h at room temperature. 
The tubes were kept at −20 °C for 2 days and then stored 
at −80  °C. Total RNA was extracted from the blood 
sample by using PaxGene Blood RNA Kit (PreAnalytiX, 
Qiagen). After RNA was qualified by Agilent 2100 Bio-
analyzer, 100  ng of total RNA was converted to cDNA, 
amplified, and labeled with Cy3-labeled CTP using the 
Quick Amp Labeling kit (Agilent Technologies, Santa 
Clara, CA). The amplified cRNA and dye incorpora-
tion were quantified using ND-1000 Spectrophotometer 
(Nano Drop Technologies, Wilmington, DE) and hybrid-
ized to SurePrint G3 Human GE Microarray 8  ×  60  k 
ver. 2.0 (Design ID: 039494, Agilent Technologies). After 
hybridization, arrays were washed consecutively by using 
Gene Expression Wash Pack (Agilent Technologies). 
Fluorescence images of the hybridized arrays were gener-
ated using the Agilent DNA Microarray Scanner, and the 
intensities were extracted with Agilent Feature Extraction 
software ver. 10.7.3.1. The raw microarray data are depos-
ited in the National Center for Biotechnology Informa-
tion Gene Expression Omnibus (GEO Series GSE85226).
Microarray data analyses
The raw microarray intensities were processed by 
the percentile shift method (75th percentile) with 
GeneSpring GX 13.0 (Agilent Technologies) so as to 
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normalize the range of expression intensities for inter-
microarray. Genes found to be expressed in more than 
50% of the hybridizations were subjected to further 
analyses. The normalized data were exported from 
the GeneSpring GX software. The univariate correla-
tion between clinical parameters, including VFA and 
SFA, and peripheral blood gene expression levels was 
examined by Pearson’s correlation under the R envi-
ronment (http://cran.at.r-project.org). Gene ontology 
(GO) information was retrieved from the annotations in 
GeneSpring GX 13.0.
Results
Characteristics of the enrolled subjects
The clinical characteristics of the participating subjects 
are listed in Table  1. The mean BMI and waist circum-
ference were 30.0  kg/m2 (range, 24.0–44.0  kg/m2) and 
101.2  cm (range, 85–127  cm), respectively. The mean 
VFA and SFA were 177.3  cm2 (range, 78–318  cm2) and 
244.7  cm2 (range, 80–558  cm2), respectively. The mean 
serum adiponectin concentration was 4.2 μg/mL (range, 
2.3–9.8  μg/mL) and the mean HbA1c was 6.3% (range, 
5.3–10.9%). Among the 17 subjects, 5 had type 2 diabe-
tes, 6 had borderline diabetes, and 6 subjects had normal 
glucose tolerance. All 5 diabetic patients were not treated 
with any anti-diabetic agents. Atherosclerotic plaque in 
the carotid artery (IMT ≥1.1 mm) was observed in 7 sub-
jects. Among the 17 subjects, dyslipidemia and hyperten-
sion were found in 15 and 8 subjects, respectively. Seven 
patients were treated with statins and four patients were 
treated with angiotensin converting enzyme inhibitor 
(ACE-I) or angiotensin II receptor blocker (ARB).
Gene expression profiles
Peripheral blood RNA samples were subjected to micro-
array analysis. The target probes were selected under the 
condition that significant signals were detected in more 
than 7 cases among 17 subjects and thus 23,197 probes 
were extracted for gene expression analysis. Table 2 lists 
the number of probes that showed significant changes 
according to various clinical variables under the statisti-
cal environment that the parametric false discovery rate 
(FDR) was less than 0.1. Sex and age had impacts on 52 
and 625 probes, respectively. Surprisingly, VFA had a 
great impact on peripheral blood cells gene expression, 
i.e., 1354 probes consisting of 307 up-regulated and 1047 
down-regulated probes. However, no significant gene 
probes were detected with SFA or BMI. Serum adiponec-
tin, diabetes, HbA1c, and HOMA-IR also had no impact 
on the gene expression in peripheral blood cells. Like-
wise, statins and ACE-I/ARB had no effect. Figure 1 illus-
trates the number of upregulated/downregulated probes 
according to various clinical parameters. Table 3 lists the 
top 30 genes that correlated significantly with VFA posi-
tively and negatively. Among these genes, Krüppel-like 
factor 10 (KLF10) was the most significant (Table 3).
Gene ontology
Gene ontology (GO) analysis was also performed to fur-
ther determine the impact of VFA on gene expression 
profile in peripheral blood cells. As shown in Table  4, 
visceral fat adiposity correlated significantly with genes 
related to the metabolic process, oxygen transport, 
and nucleotide binding. Genes involved in inflamma-
tion (GO: 0006954), oxidative stress (GO: 0006979), 
immune response (GO: 0006955), lipid metabolism (GO: 
0006629), and glucose metabolism (GO: 0006006), were 
finally examined. Figure 2 shows the percentage of genes 
(among all genes) that correlated significantly with SFA 
and VFA (p < 0.05). VFA correlated with 17.6, 26.8, 18.4, 
25.5, and 26.4% of genes involved in inflammation, oxi-
dative stress, immune response, lipid metabolism, and 
glucose metabolism, respectively, while the respective 
percentages for SFA were only 4.2, 2.6, 2.7, 3.4, and 3.2%.
Table 1 Characteristics of subjects
Data are mean ± SD
T2DM type 2 diabetes mellitus, B borderline diabetes, N normal glucose 
tolerance, HOMA-IR homeostasis model assessment of insulin resistance, HDL-C 
high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, 
eGFR estimated glomerular filtration rate, IMT intima-media thickness, ACE-I 
angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker
N 17
Sex (male/female) 14/3
Age (years) 54.6 ± 14.6
BMI (kg/m2) 30 ± 5.5
Waist circumference (cm) 101 ± 11
Visceral fat area (cm2) 177 ± 67
Subcutaneous fat area (cm2) 245 ± 131
Adiponectin (μg/mL) 4.2 ± 1.7
Systolic blood pressure (mm Hg) 132 ± 17
Diastolic blood pressure (mm Hg) 82 ± 13.7
Fast plasma glucose (mg/dL) 102 ± 21
Hemoglobin A1c (%) 6.3 ± 1.3
Diagnosis (T2DM/B/N) 5/6/6
HOMA‑IR 3.2 ± 2.3
Total cholesterol (mg/dL) 206 ± 40
Triglyceride (mg/dL) 196 ± 129
HDL‑C (mg/dL) 56.3 ± 18.1
LDL‑C (mg/dL) 114 ± 40
Uric acid (mg/dL) 6.4 ± 0.8
Urinary albumin (μg/day) 12.3 ± 10.6
eGFR (mL/min/1.73 m2) 77.9 ± 19.8
mean IMT ≥1.1 mm 7/10
Statin use (±) 7/10
ACE‑I/ARB use (±) 4/13
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Discussion
The major finding of the present study was that vis-
ceral fat, but not subcutaneous fat, in obese individuals 
had a significant impact on peripheral blood cells gene 
expression profile. While similar results were reported 
previously by our group [8, 9], these studies had several 
limitations: (1) VFA was estimated by abdominal bio-
electrical impedance analysis (BIA), rather than by CT. 
The latter is recognized as the gold standard method for 
fat area measurement [12, 15, 16]. (2) The majority of 
the subjects enrolled in the above previous studies were 
diabetics (75%) with a mean HbA1c of 8.1%. The inclu-
sion of such patients could have influenced the results. 
(3) Impact of SFA on gene expression level in peripheral 
blood cells could not be determined under abdominal 
BIA procedure. The present study is clinically more sig-
nificant as it included precise measurement of VFA and 
SFA by CT scan and negligible diabetic conditions.
The biological differences between visceral and subcuta-
neous fat have been investigated. The rate of lipolysis and 
lipogenesis activities are higher in adipocytes of visceral fat 
tissue than those of subcutaneous fat tissue [17, 18], sug-
gesting that visceral fat accumulation increases free fatty 
acids (FFA) in the portal vein, accelerates hepatic lipogen-
esis, and results in dyslipidemia involving high FFA level in 
the bloodstream. Visceral fat accumulation also enhances 
inflow of glycerol into the liver and hepatic glucose pro-
duction through adipose and hepatic glycerol channels; 
aquaporin 7 and 9, respectively [19]. Furthermore, adipose 
mRNA levels dynamically change in visceral fat compared 
to subcutaneous fat, especially in obese subjects. As BMI 
increases, the mRNA levels of adiponectin and peroxi-
some proliferator-activated receptor gamma (PPARγ) are 
reduced, while mRNA level of NADPH oxidase subu-
nit p22, promoting reactive oxygen species (ROS), is 
augmented, in visceral fat, but not in subcutaneous fat 
[20]. Visceral fat accumulation is also a major risk for the 
reduction of circulating adiponectin (hypoadiponectine-
mia) [1]. Collectively, compared to subcutaneous fat, vis-
ceral fat accumulation largely and pathologically alters 
not only its own fat tissue, but also circulating substances 
and metabolic outcome. It is therefore conceivable that 
these visceral fat-mediated changes can also alter the gene 
expression profile in peripheral blood cells.
Increasing evidence indicates that chronic low-grade 
inflammation in the adipose tissue, especially in vis-
ceral fat, is located upstream of the metabolic syndrome 
[21, 22]. Gut microbiota also accelerates inflammatory 
changes in visceral fat [7]. Various immune cells infiltrate 
adipose tissue and cause inflammatory changes through 
direct cell–cell interaction and/or indirect cytokine-
mediated intercellular communication. It is not hard to 
imagine that such interactions among immune cells and 
adipocytes influence peripheral blood cells, but such pro-
cesses have not been confirmed yet. The present study 
also suggests that gene expression profile of peripheral 
blood cells reflects local inflammatory changes in visceral 
fat.
Table 2 Changes in  probes according to  various clinical 
parameters
Data represent number of probes
FDR false discovery rate, IMT intima-media thickness, ACE-I angiotensin 
converting enzyme inhibitor, ARB angiotensin II receptor blocker, HOMA-IR 
homeostasis model assessment of insulin resistance
FDR < 0.1 Up Down
Categorical
Sex 52 20 32
Diagnosis of diabetes 0 0 0
Mean IMT 0 0 0
Statin use 0 0 0
ACE‑I/ARB use 0 0 0
Continuous
Age 625 206 419
Body mass index 0 0 0
Visceral fat area 1354 307 1047
Subcutaneous fat area 0 0 0
Adiponectin 0 0 0
Hemoglobin A1c 0 0 0




























Fig. 1 Changes in the number of genes according to various 
clinical parameters. The target 23,197 probes were selected under 
the condition that significant signals were detected in more than 7 
cases among 17 subjects. Data represent the number of probes that 
showed significant upregulation and downregulation according to 
the listed clinical parameters under the statistical environment that 
the parametric false discovery rate (FDR) was less than 0.1. Parameters 
such as sex, diagnosis for diabetes, mean IMT, statin use, and ACE‑I/
ARB use were adopted as categorical variables. Age, BMI, visceral and 
subcutaneous fat areas, adiponectin, hemoglobin A1c, and HOMA‑IR 
were adopted as continuous variables. BMI body mass index; HOMA-
IR homeostasis model assessment of insulin resistance; IMT intima‑
media thickness; ACE-I angiotensin converting enzyme inhibitor; ARB 
angiotensin II receptor blocker
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Table 3 Top 30 genes that correlated positively and negatively with visceral fat area
Probe name Gene symbol Gene name R p value FDR
Positive correlation
A_21_P0013668 SPATA31C2 SPATA31 subfamily C, member 2 0.830 3.72E−05 0.08430563
A_19_P00803850 LOC100505474 Uncharacterized LOC100505474 0.828 4.01E−05 0.08430563
A_33_P3238410 SBF1 SET binding factor 1 0.814 6.93E−05 0.08430563
A_23_P325676 ZNF653 Zinc finger protein 653 0.803 1.03E−04 0.08430563
A_23_P384532 CCDC11 Coiled‑coil domain containing 11 0.802 1.07E−04 0.08430563
A_33_P3311956 FEZ2 Fasciculation and elongation protein zeta 2 (zygin II) 0.801 1.13E−04 0.08430563
A_23_P430670 CHST5 Carbohydrate (N‑acetylglucosamine 6‑O) sulfotransferase 5 0.797 1.29E−04 0.08430563
A_33_P3253653 GPR155 G protein‑coupled receptor 155 0.779 2.29E−04 0.08430563
A_33_P3314974 PARD6G‑AS1 PARD6G antisense RNA 1 0.778 2.33E−04 0.08430563
A_33_P3402773 0.775 2.61E−04 0.084956675
A_24_P117942 TOMM20L Translocase of outer mitochondrial membrane 20 homolog 
(yeast)‑like
0.771 2.94E−04 0.084956675
A_33_P3772937 KRT8P12 Keratin 8 pseudogene 12 0.768 3.15E−04 0.084956675
A_33_P3404889 0.768 3.20E−04 0.084956675
A_33_P3379436 FAM74A4 Family with sequence similarity 74, member A4 0.767 3.29E−04 0.084956675
A_23_P34066 IL9R Interleukin 9 receptor 0.765 3.50E−04 0.084956675
A_23_P417415 ACOT11 Acyl‑CoA thioesterase 11 0.758 4.19E−04 0.084956675
A_33_P3410093 LTA4H Leukotriene A4 hydrolase 0.758 4.22E−04 0.084956675
A_33_P3334895 GRIN2A Glutamate receptor, ionotropic, N‑methyl D‑aspartate 2A 0.750 5.26E−04 0.084956675
A_23_P72697 GPIHBP1 Glycosylphosphatidylinositol anchored high density lipoprotein 
binding protein 1
0.749 5.40E−04 0.084956675
A_33_P3378531 AS3MT Arsenite methyltransferase 0.748 5.57E−04 0.084956675
A_24_P75190 HBD Hemoglobin, delta 0.747 5.76E−04 0.084956675
A_23_P26457 HBA2 Hemoglobin, alpha 2 0.744 6.08E−04 0.084956675
A_33_P3265866 0.744 6.09E−04 0.084956675
A_21_P0004859 BTN2A1 Butyrophilin, subfamily 2, member A1 0.741 6.63E−04 0.084956675
A_21_P0005185 DKFZp686L13185 Uncharacterized LOC401287 0.739 6.95E−04 0.084956675
A_21_P0012204 XLOC_014512 0.739 7.00E−04 0.084956675
A_21_P0009476 XLOC_012670 0.737 7.45E−04 0.084956675
A_33_P3365932 WASH1 WAS protein family homolog 1 0.734 7.91E−04 0.084956675
A_19_P00812257 LINC01191 Long intergenic non‑protein coding RNA 1191 0.732 8.26E−04 0.084956675
A_23_P209564 CYBRD1 Cytochrome b reductase 1 0.732 8.36E−04 0.084956675
Negative correlation
A_23_P168828 KLF10 KRUPPEL‑like factor 10 −0.856 1.16E−05 0.08430563
A_32_P54544 CCT6A Chaperonin containing TCP1, subunit 6A (zeta 1) −0.832 3.40E−05 0.08430563
A_23_P389919 WHSC1 Wolf‑Hirschhorn syndrome candidate 1 −0.830 3.74E−05 0.08430563
A_23_P44139 PRIM2 Primase, DNA, polypeptide 2 (58 kDa) −0.827 4.21E−05 0.08430563
A_19_P00331853 LOC100131564 uncharacterized LOC100131564 −0.826 4.34E−05 0.08430563
A_23_P501877 ZFP64 ZFP64 zinc finger protein −0.826 4.36E−05 0.08430563
A_24_P3973 HNRNPA2B1 Heterogeneous nuclear ribonucleoprotein A2/B1 −0.826 4.46E−05 0.08430563
A_23_P215088 ZC3HC1 Zinc finger, C3HC‑type containing 1 −0.826 4.47E−05 0.08430563
A_23_P7679 NUP155 Nucleoporin 155 kDa −0.816 6.50E−05 0.08430563
A_33_P3381483 ZNF331 Zinc finger protein 331 −0.811 7.73E−05 0.08430563
A_23_P115149 WDR77 WD repeat domain 77 −0.808 8.71E−05 0.08430563
A_23_P151093 YARS2 Tyrosyl‑tRNA synthetase 2, mitochondrial −0.807 8.92E−05 0.08430563
A_23_P251421 CDCA7 Cell division cycle associated 7 −0.807 8.94E−05 0.08430563
A_21_P0008290 LINC00641 Long intergenic non‑protein coding RNA 641 −0.807 9.17E−05 0.08430563
A_33_P3262665 MAP7D3 MAP7 domain containing 3 −0.805 9.59E−05 0.08430563
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Table 3 continued
Probe name Gene symbol Gene name R p value FDR
A_33_P3213557 CCZ1 CCZ1 vacuolar protein trafficking and biogenesis associated 
homolog (S. cerevisiae)
−0.805 9.60E−05 0.08430563
A_23_P202143 NOLC1 Nucleolar and coiled‑body phosphoprotein 1 −0.804 1.01E−04 0.08430563
A_23_P46924 BUB3 BUB3 mitotic checkpoint protein −0.803 1.04E−04 0.08430563
A_24_P925635 SEPT7P2 Septin 7 pseudogene 2 −0.803 1.06E−04 0.08430563
A_24_P345822 TFG TRK‑fused gene −0.802 1.08E−04 0.08430563
A_23_P85180 TMEM187 Transmembrane protein 187 −0.801 1.10E−04 0.08430563
A_33_P3221234 IPP Intracisternal A particle‑promoted polypeptide −0.801 1.13E−04 0.08430563
A_33_P3415037 VDAC2 Voltage‑dependent anion channel 2 −0.799 1.20E−04 0.08430563
A_33_P3309929 HDAC3 Histone deacetylase 3 −0.799 1.21E−04 0.08430563
A_23_P214798 SYNCRIP Synaptotagmin binding, cytoplasmic RNA interacting protein −0.796 1.34E−04 0.08430563
A_21_P0012709 XLOC_014512 −0.795 1.38E−04 0.08430563
A_24_P116909 MALT1 Mucosa associated lymphoid tissue lymphoma translocation 
gene 1
−0.794 1.42E−04 0.08430563
A_23_P69437 YEATS2 YEATS domain containing 2 −0.793 1.45E−04 0.08430563
A_33_P3251538 MAPKAP1 Mitogen‑activated protein kinase associated protein 1 −0.793 1.46E−04 0.08430563
A_23_P102202 MSH6 Muts homolog 6 −0.793 1.47E−04 0.08430563
Table 4 Significant GO terms based on genes that correlated positively and negatively with visceral fat area
GO GO term Corrected p value
Positive correlation
Biological process Oxygen transport 8.821E−04
Gas transport 3.707E−03
Molecular function Oxygen transporter activity 5.310E−04
Cellular component Hemoglobin complex 3.428E−04
Negative correlation
Biological process RNA processing 6.559E−21
Heterocycle metabolic process 1.252E−20
Cellular nitrogen compound metabolic process 8.348E−20
Nucleobase‑containing compound metabolic process 1.702E−19
Organic cyclic compound metabolic process 2.892E−19
Cellular aromatic compound metabolic process 6.642E−19
Cellular metabolic process 4.940E−18
Nitrogen compound metabolic process 9.293E−18
Nucleic acid metabolic process 1.052E−16
Cellular macromolecule metabolic process 1.780E−16
Metabolic process 1.122E−14
Primary metabolic process 1.551E−14
Gene expression 3.068E−14
Organic substance metabolic process 7.768E−14
Macromolecule metabolic process 1.529E−11
RNA metabolic process 3.440E−11
mRNA processing 5.194E−11
ncRNA metabolic process 1.859E−10
RNA splicing 5.494E−10
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Interestingly, KLF10, a member of the Krüppel-like 
family of transcription factors, showed the most sig-
nificant and negative correlation with VFA (Table  3). 
KLF10 is augmented through the transforming growth 
factor-β (TGF-β)-Smad signaling pathway [23]. It plays 
a crucial role in TGF-β-mediated induction of regu-
latory T-cells (Treg) from naive T-cells [24]. In mice 
lacking KLF10, Treg activity was reduced and pro-
inflammatory changes were accelerated. Transfer of 
KLF10-deficient T-cells failed to suppress the devel-
opment of atherosclerosis in apolipoprotein E knock-
out mice with high-fat diet [25]. KLF10-deficient mice 
also showed hyperglycemia in males and hypertriglyc-
eridemia in females [26]. KLF10 has been shown to 
regulate 20–30% of hepatic genes related to glucose 
and lipid metabolism [26]. Genetic variants of KLF10 
are associated with susceptibility to type 2 diabetes 
[27]. However, KLF10 mRNA expressions were not 
Table 4 continued
GO GO term Corrected p value
Molecular function RNA binding 1.470E−10
Nucleotide binding 2.106E−07
Nucleoside phosphate binding 2.143E−07
Heterocyclic compound binding 1.144E−06
Nucleic acid binding 2.081E−06
Aminoacyl‑tRNA ligase activity 2.924E−06
Ligase activity, forming aminoacyl‑tRNA and related compounds 2.924E−06
Ligase activity, forming carbon–oxygen bonds 2.924E−06
Organic cyclic compound binding 3.035E−06
Small molecule binding 3.265E−06
Catalytic activity 1.736E−04
ATP‑dependent helicase activity 3.046E−04
Purine NTP‑dependent helicase activity 3.046E−04
Structure‑specific DNA binding 3.201E−04
ATPase activity 9.197E−04
ATPase activity, coupled 1.738E−03
Adenyl nucleotide binding 1.738E−03
ATP binding 1.799E−03
Adenyl ribonucleotide binding 2.557E−03
Cellular component Nuclear part 2.984E−28
Intracellular part 6.115E−28
Intracellular 1.984E−27
Intracellular membrane‑bounded organelle 8.017E−27
Membrane‑enclosed lumen 6.105E−24
Intracellular organelle lumen 6.201E−24
Nuclear lumen 6.172E−23
Organelle lumen 8.194E−23
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significantly correlated with diabetes or dyslipidemia 
in present study. To confirm the association between 
KLF10 expressions in peripheral blood cells and dia-
betes or dyslipidemia, further investigations would be 
desired in some other populations, different from pre-
sent clinical profiles, such as non-obese or non-diabetic 
subjects. Present data provides a possibility that vis-
ceral fat adiposity-associated reduction in peripheral 
blood KLF10 mRNA level is related to the pathogenesis 
of the metabolic syndrome, although further clinical 
studies would be needed in future.
The present study has several limitations. The study 
population was small and the proportion of female was 
low. Several participants received medications such as 
statins and ACE-I/ARBs. Importantly, the majority of 
subjects were obese and showed abundant accumula-
tion of visceral fat according to the Japanese criteria; 
the study included only one subject with VFA below 
100  cm2. The full impact of VFA on the gene expres-
sion profile of peripheral blood cells has not been 
determined previously and should be examined also 
in non-obese individuals. In the present study, among 
the top 30 genes that correlated positively with VFA 
(Table 3), 14 (46.7%) genes were up-regulated in obesity, 
and among the top 30 genes that correlated negatively 
with VFA (Table 3), 17 (56.7%) genes were down-regu-
lated in obesity. Unfortunately, a control group of non-
obese subjects could not be included in the present 
study for ethical reasons (exposure of such subjects to 
CT scanning). For this reason, no data are available for 
the correlation of VFA and SFA to the gene expression 
profile of peripheral blood cells in non-obese subjects. 
Therefore, our results can only be applied to obese 
individuals.
Conclusions
The present study demonstrated that accumulation of 
visceral fat, but not that of subcutaneous fat, alters the 
gene expression profile of peripheral blood cells in obese 
Japanese subjects. The results should enhance our under-
standing of the pathogenesis of the metabolic syndrome.
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